Bryony Dawkins

Profile

Following the completion of my MSc in Health Economics, I joined the Academic Unit of Health Economics (AUHE) as a Research Assistant in 2015. In 2017, I was appointed as Research Fellow and in 2022 became Lecturer in Health Economics.

At AUHE, our team consists of around 30 researchers with expertise including economic evaluation, distributional cost-effectiveness analysis, health economic modelling, discrete choice experiments, applied econometrics, observational data analysis, systematic review and evidence synthesis.  We maintain active collaborations with many universities and policymakers in the UK and internationally.

For further information please see our newsletter and LinkedIn, or get in touch.

Research interests

My research interests include economic modelling, global health, health equity and inequalities in health and healthcare.

Current and recent research projects include:

• CHORUS: Community-led Responsive and Effective Urban Health Systems – A research programme consortium unndertaking research that responds to the practical challenges of delivering equitable health in urban areas in 4 partner countries: Bangladesh, Ghana, Nepal and Nigeria. Project wesite: https://chorusurbanhealth.org/
• GHRG-ST: Global Health Research Group - Surgical technologies:
  • FIXT: Feasibility of Ilizarov frame fiXation for closed Tibial fractures in Sierra Leone
  • TARGET: Training programme in gAsless lapaRoscopic surGery for rural surgEons of NorTh-East India
• Flair: Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes (RCT)
• RADAR: Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RCT)
• FitNEsS (Myeloma XIV): Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Symptomatic Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRDa) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I)
• Acupuncture Neuropathy (Hong Kong): A randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy (Hong Kong)
• REACH: feasibility trial: Research Exploring physical Activity in Care Homes
• Lots2Care - A longer-term care strategy to support stroke survivors and their carers (LoTS2Care) – Feasibility study
• COMDIS-HSD:
  • A pragmatic cluster randomised controlled trial for reducing irrational antibiotic prescribing among children with upper respiratory infections in rural China
  •  Enhanced diabetes-cardiovascular management through primary healthcare in Pakistan: a cluster randomised trial
• White Rose Collaboration project: Assessing the appropriateness of existing model adaption methods to the context of middle income countries: a case study on Taxanes for adjuvant treatment of early breast cancer in South Africa
• eRAPID: Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice 
• MUK Eight: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and bortezomib

Qualifications

• MSc Health Economics - University of York
• BA (Hons) Economics and History - University of Leeds

Professional memberships

• Health Economic Study Group (HESG)

Research groups and institutes

• Leeds Institute of Health Sciences
• Health economics
• Academic Unit of Health Economics
• Decision Modelling Group
• Applied Health Econometrics Group
• International health research